| pubmed-article:1735769 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0021083 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0206726 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0006118 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0021745 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0024518 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0332448 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C1710493 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:1735769 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:1735769 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1735769 | pubmed:dateCreated | 1992-3-6 | lld:pubmed |
| pubmed-article:1735769 | pubmed:abstractText | Effects of gamma-interferon (IFN-gamma) on immune parameters in the 9L gliosarcoma model were examined. IFN-gamma increased class I major histocompatibility complex (MHC) expression in 9L cells in vitro. In vivo, intratumor injections of IFN-gamma led to increased numbers of inflammatory cells within the tumor and class II+ mononuclear phagocytes at its periphery, and increased MHC class I or II expression by endothelial and ependymal cells. Class I expression in 9L cells themselves was not increased. This suggests that there may be inhibition of class I induction in vivo for certain cell types, for which immunotherapies based on non-MHC restricted mechanisms may be more effective. | lld:pubmed |
| pubmed-article:1735769 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1735769 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1735769 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1735769 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1735769 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1735769 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1735769 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1735769 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1735769 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:1735769 | pubmed:issn | 0165-5728 | lld:pubmed |
| pubmed-article:1735769 | pubmed:author | pubmed-author:LampsonL ALA | lld:pubmed |
| pubmed-article:1735769 | pubmed:author | pubmed-author:WenP YPY | lld:pubmed |
| pubmed-article:1735769 | pubmed:author | pubmed-author:LampsonM AMA | lld:pubmed |
| pubmed-article:1735769 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1735769 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:1735769 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1735769 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1735769 | pubmed:pagination | 57-68 | lld:pubmed |
| pubmed-article:1735769 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:meshHeading | pubmed-meshheading:1735769-... | lld:pubmed |
| pubmed-article:1735769 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1735769 | pubmed:articleTitle | Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. | lld:pubmed |
| pubmed-article:1735769 | pubmed:affiliation | Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115. | lld:pubmed |
| pubmed-article:1735769 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1735769 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1735769 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
